STOCK TITAN

Trevi Therapeutics (TRVI) NEA funds report 11.6% beneficial ownership

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Trevi Therapeutics, Inc. received an updated Schedule 13D/A from New Enterprise Associates–affiliated funds and managers, correcting earlier disclosures after exercises of certain NEA 16 warrants and acquisition of the underlying common shares before Amendment No. 7.

As of February 13, 2026, the NEA funds report beneficial ownership of a combined 15,074,080 shares of Trevi common stock, representing 11.6% of the class, based on 130,081,986 shares including NEA 16 warrants. This includes 12,273,280 shares held by NEA 16 and 948,948 shares held by NEA 18 Venture Growth Equity, plus 1,851,852 shares underlying NEA 16 warrants. Individual manager Forest Baskett is deemed to beneficially own 14,125,132 shares, or 10.9%. The filing states the firm shares were acquired for investment purposes and notes no specific current plans for corporate changes, though the funds may buy or sell additional shares over time.

Positive

  • None.

Negative

  • None.





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


New Enterprise Associates 16, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
NEA Partners 16, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
NEA 16 GP, LLC
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
NEA 18 Venture Growth Equity, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
NEA Partners 18 VGE, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
NEA 18 VGE GP, LLC
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
Forest Baskett
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Forest Baskett
Date:02/13/2026
Ali Behbahani
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Ali Behbahani
Date:02/13/2026
Carmen Chang
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Carmen Chang
Date:02/13/2026
Anthony A. Florence, Jr.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr.
Date:02/13/2026
Mohamad H. Makhzoumi
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi
Date:02/13/2026
Scott D. Sandell
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Scott D. Sandell
Date:02/13/2026
Paul Walker
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Paul Walker
Date:02/13/2026
Comments accompanying signature:
This Amendment No. 8 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

FAQ

What does the latest Schedule 13D/A reveal about NEA’s stake in Trevi Therapeutics (TRVI)?

The filing shows NEA-affiliated funds beneficially own 15,074,080 Trevi shares, or 11.6% of the common stock. This combines NEA 16 and NEA 18 Venture Growth Equity positions, including shares underlying NEA 16 warrants, based on 130,081,986 shares outstanding.

How many Trevi Therapeutics (TRVI) shares does NEA 16 report owning?

NEA 16 reports 12,273,280 Trevi common shares plus 1,851,852 underlying NEA 16 warrants, collectively termed the NEA 16 Shares. Through related general partners and managers, several affiliated NEA entities are deemed to beneficially own these same shares for Schedule 13D reporting purposes.

Why was Amendment No. 8 to the Trevi Therapeutics (TRVI) Schedule 13D filed?

Amendment No. 8 was filed to correct beneficial ownership disclosures for NEA-affiliated reporting persons. It updates the reported Trevi common stock holdings to reflect prior exercises of certain NEA 16 warrants and acquisition of the underlying shares that occurred before Amendment No. 7.

What percentage of Trevi Therapeutics (TRVI) does Forest Baskett report beneficially owning?

Forest Baskett is deemed to beneficially own 14,125,132 shares of Trevi common stock, representing 10.9% of the outstanding class. This interest arises through his role as a manager of NEA 16 GP, LLC, which controls the NEA 16 fund holding Trevi shares and warrants.

Does NEA plan any major corporate actions at Trevi Therapeutics (TRVI)?

The filing states the NEA funds acquired Trevi shares for investment purposes and list no current plans for mergers, asset sales, board changes, or other major corporate actions. They may still buy or sell additional Trevi shares depending on market conditions and ongoing evaluations.

How was NEA’s ownership percentage in Trevi Therapeutics (TRVI) calculated?

The 11.6% ownership figure uses a base of 130,081,986 Trevi shares. This includes 128,230,134 common shares reported outstanding as of October 31, 2025 in Trevi’s Form 10-Q, plus shares issuable upon exercise of the NEA 16 warrants held by NEA 16.
Trevi Therapeutics

NASDAQ:TRVI

TRVI Rankings

TRVI Latest News

TRVI Latest SEC Filings

TRVI Stock Data

1.33B
113.69M
0.72%
92.78%
9.6%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN